GLP-1 and Type 2 Diabetes Weight Loss: A Comprehensive Overview
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have revolutionized the management of type 2 diabetes mellitus in recent years. These medications have not only improved glycemic control but also led to significant weight loss in patients with type 2 diabetes. In this article, we will delve into the mechanism of action of GLP-1RAs, their clinical implications, and the benefits of GLP-1 and type 2 diabetes weight loss.
What are GLP-1 Receptor Agonists?
GLP-1RAs are a class of medications that mimic the action of the glucagon-like peptide-1 (GLP-1) hormone. GLP-1 is an incretin hormone released from the intestines in response to food intake. It stimulates insulin secretion, suppresses glucagon secretion, and slows gastric emptying. By mimicking the action of GLP-1, GLP-1RAs enhance insulin release, reduce glucose production in the liver, and decrease gastric emptying, leading to improved glycemic control and weight loss.
Clinical Implications of GLP-1RAs
The use of GLP-1RAs in the management of type 2 diabetes has increased significantly over the past 10 years. Semaglutide and liraglutide are two of the most widely used GLP-1RAs, and they have been shown to promote significant weight loss in patients with type 2 diabetes. These medications have also been associated with cardiorenal benefits, reducing the risk of heart attack, stroke, and kidney disease in patients with type 2 diabetes.
-p-1080.png "Almost half of those stopping GLP-1 weight-loss drugs keep the weight off")
